Akebia licenses Vafseo to Medice for Europe, Australia; $10M upfront, up to $100M milestones

Akebia Therapeutics, Inc.

Medice gets exclusive rights to market Vafseo (vadadustat) for anemia in CKD dialysis patients in EEA, UK, Switzerland, Australia.
Akebia receives $10M upfront, up to $100M in commercial milestones, and tiered royalties of 10-30% of net sales.
Akebia retains 70% of net profit from non-dialysis population if it develops that indication; Medice commercializes both.
Vafseo approved in 33 countries; regulatory opinions expected in Switzerland and Australia later in 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Akebia Therapeutics, Inc. entered into License Agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG valued at $10 million (effective 2023-05-24).

Action: entry
Agreement: license
Counterparty: MEDICE Arzneimittel Pütter GmbH & Co. KG
Value: $10 million
Effective: 2023-05-24

Exact text from the filing

On May 24, 2023 (the “Effective Date”), Akebia Therapeutics, Inc. (the “Company”) and MEDICE Arzneimittel Pütter GmbH & Co. KG (“Medice”) entered into a License Agreement (the “License Agreement”)

View on SEC.gov

Browse all material agreements →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-019654

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.